Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2131 to 2145 of 8906 results

  1. Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]

    Awaiting development Reference number: GID-TA11855 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]

    Awaiting development Reference number: GID-HST10022 Expected publication date: TBC

    Highly specialised technologies guidance
    Awaiting development

  3. Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]

    In development Reference number: GID-TA11445 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]

    Awaiting development Reference number: GID-TA11659 Expected publication date:  13 May 2027

    Technology appraisal guidance
    Awaiting development

  5. Kidney Cancer

    In development Reference number: GID-NG10398 Expected publication date:  19 March 2026

    NICE guideline
    In development

  6. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  08 October 2027

    NICE guideline
    In development

  7. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development Reference number: GID-TA11096 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

    Awaiting development Reference number: GID-TA11686 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]

    In development Reference number: GID-TA11687 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

    In development Reference number: GID-TA10024 Expected publication date:  28 June 2017

    Technology appraisal guidance
    In development

  11. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 13 February 2026.

    Technology appraisal guidance
    In consultation

  12. Guidance on the use of electroconvulsive therapy: review proposal consultation

    We are listening to your views on this Technology appraisal guidance. Comments close 16 February 2026.

    Technology appraisal guidance
    In consultation

  13. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    Awaiting development Reference number: GID-TA11509 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Orforglipron for managing overweight and obesity ID6516

    In development Reference number: GID-TA11650 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Surgical mesh for ventral hernias

    In development Reference number: GID-HTE10080 Expected publication date: TBC

    Health technology evaluations
    In development